Given that IFN-γ has a very short half-life in serum, and manifests significant toxic side effects following systemic administration, achieving bioactive concentrations of IFN-γ at the tumor represents a significant clinical challenge [24], [25]. The gene discussed is IFNG; the disease is neoplasm.